Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease

NCT02880956 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02880956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02880956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2017
Completion date
July 28, 2021
Enrollment
453 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease